The Nile SIR sirolimus eluting intracoronary stent system will be exclusively and specifically intended for use in the treatment of patients with pathological de novo coronary arteries lesions located on bifurcation sites.

The Nile SIR is a dedicated bifurcation sirolimus eluting stent for bifurcation lesions using an abluminal coating with a biodegradable polymer matrix. The drug is entirely eluted after 9 months with no residual polymer, completing conversion to bare metal stent.